These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 35702871)

  • 21. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific Antibodies for the Treatment of Multiple Myeloma.
    Goldsmith SR; Streeter S; Covut F
    Curr Hematol Malig Rep; 2022 Dec; 17(6):286-297. PubMed ID: 36029366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
    Fei K; Ni H; Zhu M; Kuang Z; Wu M; Wu Z; Wang F; Zhou S; Jing H; Wu W; Wu D; Bai D; Chen B
    Cancer Lett; 2022 Jun; 536():215663. PubMed ID: 35381307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCMAxCD3 Bispecific Yields Robust Responses in Myeloma.
    Cancer Discov; 2023 Jun; 13(6):1280. PubMed ID: 37075091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bispecific antibodies in the treatment of multiple myeloma.
    Devasia AJ; Chari A; Lancman G
    Blood Cancer J; 2024 Sep; 14(1):158. PubMed ID: 39266530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
    Reynolds G; Cliff ERS; Mohyuddin GR; Popat R; Midha S; Liet Hing MN; Harrison SJ; Kesselheim AS; Teh BW
    Blood Adv; 2023 Oct; 7(19):5898-5903. PubMed ID: 37467036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
    Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
    Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
    Baeuerle PA; Wesche H
    Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
    Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
    Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bispecific Antibodies in Multiple Myeloma: Present and Future.
    Lancman G; Sastow DL; Cho HJ; Jagannath S; Madduri D; Parekh SS; Richard S; Richter J; Sanchez L; Chari A
    Blood Cancer Discov; 2021 Sep; 2(5):423-433. PubMed ID: 34661161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement.
    Heerma van Voss MR; Molenaar RJ; Korst CLBM; Bartelink IH; Baglio SR; Kruyswijk S; de Ruijter M; Zweegman S; Kuipers MT; van de Donk NWCJ
    Expert Opin Biol Ther; 2024 Sep; 24(9):889-901. PubMed ID: 39185748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.
    Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
    Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.
    Peng F; Wang Y; Zhao J; Liu H; Liu Z; Ding K; Zhang H; Fu R
    Br J Haematol; 2023 May; 201(3):417-421. PubMed ID: 35594370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
    Parrondo RD; Ailawadhi S; Cerchione C
    Front Oncol; 2024; 14():1394048. PubMed ID: 38660139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies and bispecifics for multiple myeloma: effective effector therapy.
    Cipkar C; Chen C; Trudel S
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):163-172. PubMed ID: 36485135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
    Pillarisetti K; Edavettal S; Mendonça M; Li Y; Tornetta M; Babich A; Majewski N; Husovsky M; Reeves D; Walsh E; Chin D; Luistro L; Joseph J; Chu G; Packman K; Shetty S; Elsayed Y; Attar R; Gaudet F
    Blood; 2020 Apr; 135(15):1232-1243. PubMed ID: 32040549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.